Compare Capri Holdings Ltd (CPRI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 75.9× Capri Holdings Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | VRTX | |
|---|---|---|
Market Cap | $1.75B | $132.79B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $529.65 |
52-Week Low | $14.98 | $376.62 |
Enterprise Value | $3.03B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $15.295, up 2.1% today but near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with moving averages indicating selling pressure, while fundamentals reveal mixed performance - strong gross margins of 62.71% but recent net losses and declining revenue. Recent Q1 2027 earnings beat expectations despite revenue challenges, with the company revising full-year guidance downward due to Michael Kors inventory delays and softer luxury demand.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with Wall Street maintaining a cautious stance (44% buy ratings) despite a $19.60 consensus target representing 28% upside. Key risks include ongoing revenue declines, luxury market volatility, and execution challenges in revitalizing the Michael Kors brand amid competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
